LUND, SE / ACCESSWIRE / May 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)
Spago Nanomedical’s annual report for 2023 is from today available at the company’s website, https://spagonanomedical.se/investor-relations/#financial-reports
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company.
Attachments
SOURCE: Spago Nanomedical
View the original press release on accesswire.com
TOKYO, Feb. 2, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a…
TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- Happy Panda announces its official market launch with a…
GARDENA, Calif., Feb. 2, 2026 /PRNewswire/ -- FUGO Precision 3D, developer of the world's first all-in-one…
OXNARD, CA / ACCESS Newswire / February 2, 2026 / Quality Dental Services functions as…
Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…
BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…